An interventional study of VytronUS Ablation System in Paroxysmal Atrial Fibrillation, sponsored by VytronUS, Inc.. Completed at 1 site in Czech Republic. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-29.
Sponsored by VytronUS, Inc. · Not applicable, Interventional, and Treatment
The objective of this investigation is to evaluate whether pulmonary vein isolation using the VytronUS ablation system is safe and effective acutely and at 3 months.
3,870 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.
This study's enrollment of 7 is below the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →VytronUS, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treatment with the VytronUS Ablation System.
Device: VytronUS Ablation System
Pulmonary vein isolation.
Device or procedure related adverse events.
Time frame: Three months post procedure.
Pulmonary vein isolation.
Time frame: Three months post procedure.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VytronUS, Inc.